Polysciences, Inc. Appoints Dr. Joël Coret as New Chief Technology Officer

Dr. Joël Coret will take over for Dr. Robert Gleim, who retired in March, as CTO and VP of the Custom Synthesis Division at Polysciences, Inc. Dr. Coret brings a wealth of experience in the research and development of active delivery and novel formulation technologies.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
We are excited to have Dr. Coret join us with his experience in active delivery and novel formulation technologies.

Warrington, PA (PRWEB) April 10, 2014

Polysciences, Inc., an award-winning company specializing in the development and manufacture of high purity chemicals and reagents for laboratory research, histology, healthcare diagnostics and medical devices, has named Dr. Joël Coret as Chief Technology Officer. Dr. Coret will assume the responsibilities of Dr. Robert Gleim, Ph.D. who retired in March after 8 years at Polysciences as Chief Technology Officer & Vice President, Custom Synthesis Division.

Dr. Coret brings over 20 years of experience in the chemical industry, focused on technology development, developing IP and IP position strategies, as well as building relationships with external partners. Prior to joining Polysciences, Dr. Coret served as Director of New Ventures at TRI Princeton in Princeton, NJ heading up research and testing activities, providing instrumentation-based, quantitative performance assessment of industrial and consumer products as well as delivery and uptake mechanisms for formulations. Dr. Coret has served tenures at Rhodia, Inc., Witco Corp. and Rhone-Poulenc. Dr. Coret is particularly interested in interfacial sciences, active delivery and bio-availability with an emphasis on practical innovations that lead to improved products.

Commenting on Coret's appointment, Polysciences President & CEO Michael Ott said, “While we will surely miss Dr. Gleim’s expertise, we are excited to have Dr. Coret join us with his experience in active delivery and novel formulation technologies. His involvement will assist us in continuing to provide flexible support to our customers as well as develop commercial opportunities in the medical device and drug delivery segments.”

Dr. Coret studied Physical and Organic Chemistry at Paul Sabatier University and the Polytechnic Institute in Toulouse, France and received his doctorate for his research on delivery of actives across bio-membranes from Joseph Fourier University in Grenoble, France. Specializing in interfacial chemistry, he has studied the optimization of active delivery from formulations in a number of industrial, agricultural and consumer applications.

About Polysciences Inc.:
Polysciences Inc. was founded in 1961 and specializes in the development and manufacture of high purity chemicals and reagents for laboratory research, histology, healthcare diagnostics and medical devices. Materials developed for the biomedical and pharmaceutical industries have helped bring about countless innovations in healthcare as well as in high performance adhesives and personal care products. More information about Polysciences, Inc. can be found at http://www.polysciences.com


Contact